Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

NCT02567435 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

325

Enrollment

NIH

Sponsor class

Conditions

Alveolar Rhabdomyosarcoma
Botryoid-Type Embryonal Rhabdomyosarcoma
Embryonal Rhabdomyosarcoma
Rhabdomyosarcoma
Sclerosing Rhabdomyosarcoma
Spindle Cell Rhabdomyosarcoma

Interventions

DRUG: Cyclophosphamide
BIOLOGICAL: Dactinomycin
DRUG: Irinotecan Hydrochloride
OTHER: Laboratory Biomarker Analysis
OTHER: Questionnaire Administration
RADIATION: Radiation Therapy
DRUG: Temsirolimus
DRUG: Vincristine Sulfate
DRUG: Vinorelbine

Sponsor

National Cancer Institute (NCI)